


This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended): ~~A compound~~ Compounds of the formula I



in which

$R^1, R^2, R^3$  ~~are~~ are each, independently of one another, ~~denote~~ are R, Hal, CN, NO<sub>2</sub>, NHR, NRR, NHCOR, NHSO<sub>2</sub>R, OR, CO-R, CO-NHR, CF<sub>3</sub>, OCF<sub>3</sub>, SCF<sub>3</sub>, SO<sub>3</sub>R, SO<sub>2</sub>R, SO<sub>2</sub>NR, SR, COOH or COOR,

R ~~is denotes~~ is H or unsubstituted or mono-, di-, tri- or tetra-R<sup>4</sup>-substituted A, Ar, Het, (CH<sub>2</sub>)<sub>q</sub>Het or (CH<sub>2</sub>)<sub>q</sub>Ar,

A ~~is denotes~~ is unbranched, branched or cyclic alkyl having 1-14 C atoms, in which one or two CH<sub>2</sub> groups ~~are each optionally may be~~ are each optionally replaced by O, S, or ~~or S~~ atoms ~~and/or by -CH=CH- groups and/or in addition 1-7 H atoms are each optionally may be~~ optionally may be replaced by F ~~or and/or~~ Cl,

Ar ~~is denotes~~ is phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted by A, Hal, OH, OA, CN, NO<sub>2</sub>, NH<sub>2</sub>, NHA, NA<sub>2</sub>, NHCOA, SCF<sub>3</sub>, SO<sub>2</sub>A, COOH, COOA, CONH<sub>2</sub>, CONHA, CONA<sub>2</sub>, NHSO<sub>2</sub>A, SO<sub>2</sub>NH<sub>2</sub>, SO<sub>2</sub>NHA, SO<sub>2</sub>NA<sub>2</sub>, CHO or COA,

Het ~~is denotes~~ is a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by carbonyl oxygen, Hal, A, -(CH<sub>2</sub>)<sub>b</sub>-Ar, -(CH<sub>2</sub>)<sub>b</sub>-cycloalkyl, OH, OA, NH<sub>2</sub>, NHA, NA<sub>2</sub>, NO<sub>2</sub>, CN, COOH, COOA, CONH<sub>2</sub>, CONHA, CONA<sub>2</sub>, NHCOA, NHCONH<sub>2</sub>, NHSO<sub>2</sub>A, CHO, COA, SO<sub>2</sub>NH<sub>2</sub> and/or S(O)<sub>g</sub>A,

Hal	<u>is</u> <del>denotes</del> F, Cl, Br or I,
R <sup>4</sup>	<u>is</u> <del>denotes</del> Hal, OH, CN, NO <sub>2</sub> , CF <sub>3</sub> , OCF <sub>3</sub> , SCF <sub>3</sub> , SO <sub>2</sub> A or OA,
X	<u>is</u> <del>denotes</del> O, S, SO <sub>2</sub> NH or NH,
(Y)	<u>is</u> <del>denotes</del> phenyl or a monocyclic aromatic heterocycle having 1 to 4 N, O and/or S atoms,
b [[.]]	<u>is</u> <del>denotes</del> 0, 1, 2, 3 or 4,
g	<u>is</u> <del>denotes</del> 0, 1 or 2,
n, m, p, q	<u>are</u> <del>each, independently of one another, denote</del> 1, 2, 3, or 4,

or a ~~and~~ pharmaceutically acceptable salt, derivative, solvate or stereoisomer salts,  
~~derivatives, solvates and stereoisomers thereof, including mixtures thereof in~~  
~~all ratios.~~

2. (Currently Amended): A compound ~~Compounds~~ according to Claim 1, in  
 which R<sup>1</sup> is ~~denotes~~ Hal, NO<sub>2</sub>, CF<sub>3</sub>, COOH, COOR or H;  
~~and pharmaceutically acceptable salts, derivatives, solvates and stereoisomers thereof,~~  
~~including mixtures thereof in all ratios.~~

3. (Currently Amended): A compound ~~Compounds~~ according to Claim 1, in  
 which R<sup>2</sup> is ~~denotes~~ H;  
~~and pharmaceutically acceptable salts, derivatives, solvates and stereoisomers thereof,~~  
~~including mixtures thereof in all ratios.~~

4. (Currently Amended): A compound ~~Compounds~~ according to claim 1, in  
 which R<sup>3</sup> is ~~denotes~~ H, Hal or CO-NHR;  
~~and pharmaceutically acceptable salts, derivatives, solvates and stereoisomers thereof,~~  
~~including mixtures thereof in all ratios.~~

5. (Currently Amended): A compound ~~Compounds~~ according to claim 1, in  
 which (Y) is ~~denotes~~ phenyl, furyl, thienyl, pyrrolyl, imidazolyl, pyridyl or pyrimidinyl;  
~~and pharmaceutically acceptable salts, derivatives, solvates and stereoisomers thereof,~~

including mixtures thereof in all ratios.

6. (Currently Amended): A compound ~~Compounds~~ according to Claim 1, in which

R<sup>1</sup> ~~is~~ denotes Hal, NO<sub>2</sub>, CF<sub>3</sub>, COOH, COOR or H,

R<sup>2</sup> ~~is~~ denotes H,

R<sup>3</sup> ~~is~~ denotes H, Hal, CO-NHR,

Y ~~is~~ denotes phenyl, furyl, thienyl, pyrrolyl, imidazolyl, pyridyl or pyrimidinyl,

X ~~is~~ denotes O, S, SO<sub>2</sub>NH or NH,

n, p, are each, independently of one another, ~~denote~~ 1, 2, 3 or 4,

m ~~is~~ denotes 1;

~~and pharmaceutically acceptable salts, derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.~~


7. (Currently Amended): A compound ~~Compounds~~ according to Claim 1 selected from the group

- a) benzoxazol-2-yl-[4-(pyridin-4-yloxy)phenyl]amine,
- b) benzoxazol-2-yl-[4-(pyridin-4-ylsulfanyl)phenyl]amine,
- c) N-benzoxazol-2-yl-N'-pyridin-4-ylbenzene-1,4-diamine,
- d) 2-[4-(pyridin-4-ylsulfanyl)phenylamino]benzoxazole-5-carboxylic acid,
- e) 2-[4-(pyridin-4-yloxy)phenylamino]benzoxazole-6-carboxylic acid,
- f) 2-[4-(pyridin-4-ylsulfanyl)phenylamino]benzoxazole-6-carboxylic acid,
- g) methyl 2-[4-(pyridin-4-ylamino)phenylamino]benzoxazole-6-carboxylate,
- h) (5-nitrobenzoxazol-2-yl)-[4-(pyridin-4-ylsulfanyl)phenyl]amine,
- i) (5-nitrobenzoxazol-2-yl)-[4-(pyridin-4-yloxy)phenyl]amine,
- j) N-(5-nitrobenzoxazol-2-yl)-N'-pyridin-4-ylbenzene-1,4-diamine,
- k) (6-nitrobenzoxazol-2-yl)-[4-(pyridin-4-yloxy)phenyl]amine,


- h) (6-nitrobenzoxazol-2-yl)-[4-(pyridin-4-ylsulfanyl)phenyl]amine,
- iii) N-(6-nitrobenzoxazol-2-yl)-N'-pyridin-4-ylbenzene-1,4-diamine,
- n) (5-chloro-7-nitrobenzoxazol-2-yl)-[4-(pyridin-4-yloxy)phenyl]amine,
- o) (5-chloro-7-nitrobenzoxazol-2-yl)-[4-(pyridin-4-ylsulfanyl)phenyl]-amine,
- p) N-(5-chloro-7-nitrobenzoxazol-2-yl)-N'-pyridin-4-ylbenzene-1,4-diamine,
- q) (7-bromo-5-trifluoromethylbenzoxazol-2-yl)-[4-(pyridin-4-yloxy)-phenyl]amine,
- r) (7-bromo-5-trifluoromethylbenzoxazol-2-yl)-[4-(pyridin-4-ylsulfanyl)-phenyl]amine,
- s) (7-bromo-5-trifluoromethylbenzoxazol-2-yl)-[4-(4-fluorophenylsulfanyl)phenyl]amine,
- t) N-[4-(bromotrifluoromethylbenzoxazol-2-ylamino)phenyl]-4-fluorobenzenesulfonamide,
- u) [4-(2-amino-6-methylpyrimidin-4-yloxy)phenyl]-(7-bromo-5-trifluoromethylbenzoxazol-2-yl)amine,
- v) N-methyl-4-[4-(bromotrifluoromethylbenzoxazol-2-ylamino)phenoxy]-pyridine-2-carboxamide,
- w) N-methyl-4-[4-(bromotrifluoromethylbenzoxazol-2-ylamino)phenyl-sulfanyl]pyridine-2-carboxamide,
- x) (7-bromo-5-trifluoromethylbenzoxazol-2-yl)-[4-(2,4-difluorophenyl-sulfanyl)phenyl]amine,

and pharmaceutically acceptable salts, derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

8 (Currently Amended): A process ~~Process~~ for the preparation of a compound according to claim 1, said process comprising: compounds of the formula I and physiologically acceptable salts, derivatives, solvates and stereoisomers thereof, characterised in that reacting a compound of the formula II



in which  $R^1$  and  $n$  have the meanings indicated in Claim 1,  
is reacted with a compound of the formula III



in which  $R^2$ ,  $R^3$ , X, Y,  $m$  and  $p$  have the meanings indicated in Claim 1, and/or a  
base or acid of the formula I is converted into one of its salts.

9. (Currently Amended): A pharmaceutical composition ~~Medicaments~~  
comprising at least one compound according to claim 1 ~~and/or physiologically acceptable~~  
~~salts, derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios,~~  
~~and optionally~~ and one or more excipients and/or adjuvants.

10. (Currently Amended): A pharmaceutical composition ~~Medicaments~~  
comprising at least one compound according to claim 1 ~~and/or physiologically acceptable~~  
~~salts, derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios,~~  
and at least one further medicament active ingredient.

11. (Currently Amended): A kit Set (kit) consisting of separate packs of  
a) an effective amount of a compound according to claim 1 ~~and/or~~  
~~physiologically acceptable derivatives, solvates and stereoisomers thereof,~~  
~~including mixtures thereof in all ratios, and~~

b) an effective amount of a further medicament active ingredient.

12. (Cancelled):

13. (Cancelled):

14. (Currently Amended): A method of treating a patient suffering from a cancerous disease comprising administering to said patient an effective amount of a compound Use of compounds according to claim 1 ~~and/or physiologically acceptable salts, derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment and/or prophylaxis of diseases.~~

15. (Currently Amended): A method of treating a patient suffering from a disease that is Use of compounds according to claim 1 ~~and/or physiologically acceptable salts, derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment and/or prophylaxis of diseases that are caused, mediated and/or propagated by kinases and/or by kinase-mediated signal transduction,~~ comprising administering to said patient an effective amount of a compound according to claim 1.

16. (Currently Amended): A method Use according to Claim 15, where the kinases are selected from ~~the group of the~~ tyrosine kinases.

17. (Currently Amended): A method Use according to Claim 16, where the tyrosine kinases are TIE-2 or VEGFR.

18. (Currently Amended): A method Use according to Claim 15, where the kinases are selected from ~~the group of the~~ Raf kinases.

19. (Currently Amended): A method Use according to Claim 18, where the Raf kinases are A-Raf, B-Raf or Raf-1.

20. (Currently Amended): A method for treating a solid tumor in a patient comprising administering to said patient an effective amount of a compound Use of compounds according to claim 1 and/or physiologically acceptable salts, derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment and/or prophylaxis of solid tumours.

21. (Currently Amended): A method Use according to Claim 20, where the solid tumour is selected from ~~the group consisting of~~ brain tumour, tumour of the urogenital tract, tumour of the lymphatic system, stomach tumour, laryngeal tumour, and lung tumour.

22. (Currently Amended): A method Use according to Claim 20, where the solid tumour is selected from ~~the group consisting of~~ monocytic leukaemia, lung adenocarcinoma, small cell lung carcinomas, pancreatic cancer, glioblastomas, and breast carcinoma.

23. (Currently Amended): A method for treating a patient suffering from a disease that is Use of compounds according to claim 1 and/or physiologically acceptable salts, derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment and/or prophylaxis of diseases that are caused, mediated and/or propagated by angiogenesis, comprising administering to said patient an effective amount of a compound according to claim 1.

24. (Currently Amended): A method for treating a patient suffering from Use of compounds according to claim 1 and/or physiologically acceptable salts, derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment and/or prophylaxis of diseases selected from the group consisting of retinal vascularisation, diabetic retinopathy, age-induced macular degeneration and/or an inflammatory diseases disease, comprising administering to said patient an effective amount of a compound according to claim 1.

25. (Currently Amended): A method for treating a patient suffering from Use of

compounds according to claim 1 and/or physiologically acceptable salts, derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment and/or prophylaxis of bone pathologies selected from the group consisting of osteosarcoma, osteoarthritis, or and rickets, comprising administering to said patient an effective amount of a compound according to claim 1.

26. (Currently Amended): A method for treating a patient suffering from Use of compounds according to claim 1 and/or physiologically acceptable salts, derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment and/or prophylaxis of diseases selected from the group consisting of psoriasis, rheumatoid arthritis, contact dermatitis, delayed hypersensitivity reaction, inflammation, endometriosis, scarring, benign prostatic hyperplasia, an immunological disease diseases, an autoimmune disease, or an diseases and immunodeficiency disease, diseases comprising administering to said patient an effective amount of a compound according to claim 1.

27. (Currently Amended): A method for treating a patient suffering from Use of compounds according to claim 1 and/or physiologically acceptable salts, derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment and/or prophylaxis of diseases selected from the group consisting of brain cancer, lung cancer, squamous cell cancer, bladder cancer, gastric cancer, pancreatic cancer, hepatic cancer, renal cancer, colorectal cancer, breast cancer, head cancer, neck cancer, oesophageal cancer, gynaecological cancer, thyroid cancer, lymphoma, chronic leukaemia, or and acute leukaemia, comprising administering to said patient an effective amount of a compound according to claim 1.

28. (Currently Amended): A method according to claim 1, wherein said Use of compounds according to claim 1 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment and/or prophylaxis of diseases, where a therapeutically effective amount of a compound according to claim 1 is administered in combination with a compound selected from the group 1) oestrogen receptor modulators



modulator, 2) androgen receptor modulators modulator, 3) retinoid receptor modulators modulator, 4) cytotoxic agents agent, 5) antiproliferative agents agent, 6) prenyl-protein transferase inhibitors, 7) HMG-CoA reductase inhibitors, 8) HIV protease inhibitors 9) reverse transcriptase inhibitors, 10) growth factor receptor inhibitors, and 11) angiogenesis inhibitors.

29. (Currently Amended): A method according to claim 1, wherein said Use of compounds according to claim 1 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment and/or prophylaxis of diseases, where a therapeutically effective amount of a compound according to claim 1 is administered in combination with radiotherapy and

a compound selected from the group 1) oestrogen receptor modulators modulator, 2) androgen receptor modulators modulator, 3) retinoid receptor modulators modulator, 4) cytotoxic agents agent, 5) antiproliferative agents agent, 6) prenyl-protein transferase inhibitors, 7) HMG-CoA reductase inhibitors, 8) HIV protease inhibitors 9) reverse transcriptase inhibitors, 10) growth factor receptor inhibitors, and 11) angiogenesis inhibitors, and radiotherapy.

30. (New): A compound according to claim 1, wherein A is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, 1-, 2- or 3-methylbutyl, 1,1-, 1,2- or 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-, 2-, 3- or 4-methylpentyl, 1,1-, 1,2-, 1,3-, 2,2-, 2,3- or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, 1,1,2- or 1,2,2-trimethylpropyl, linear or branched heptyl, octyl, nonyl, decyl, trifluoromethyl, pentafluoroethyl, 1,1,1-trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl.

31. (New): A compound according to claim 30, wherein A is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, or tert-butyl.

32. (New): A compound according to claim 30, wherein A is alkyl having 1, 2, 3, 4, 5 or 6 C atoms, in which one or two CH<sub>2</sub> groups are each optionally replaced by O, S, or by -CH=CH-, and 1-7 H are each optionally replaced by F or Cl.

33. (New): A compound according to claim 30, wherein A is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, trifluoromethyl, pentafluoroethyl, or 1,1,1-trifluoroethyl.

34. (New): A compound according to claim 1, wherein Ar is phenyl, naphthyl or biphenyl, which in each case is mono-, di- or trisubstituted by substituents selected from A, fluorine, chlorine, bromine, iodine, hydroxyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, nitro, cyano, formyl, acetyl, propionyl, trifluoromethyl, amino, methylamino, ethylamino, dimethylamino, diethylamino, benzyloxy, sulfonamido, methylsulfonamido, ethylsulfonamido, propylsulfonamido, butylsulfonamido, dimethylsulfonamido, phenylsulfonamido, carboxyl, methoxycarbonyl, ethoxycarbonyl, and aminocarbonyl.

35. (New): A compound according to claim 1, wherein Het is 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, furthermore preferably 1,2,3-triazol-1-, -4- or -5-yl, 1,2,4-triazol-1-, -3- or -5-yl, 1- or 5-tetrazolyl, 1,2,3-oxadiazol-4- or -5-yl, 1,2,4-oxadiazol-3- or -5-yl, 1,3,4-thiadiazol-2- or -5-yl, 1,2,4-thiadiazol-3- or -5-yl, 1,2,3-thiadiazol-4- or -5-yl, 3- or 4-pyridazinyl, pyrazinyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 4- or 5-isindolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6- or 7-benzopyrazolyl, 2-, 4-, 5-, 6- or 7-benzoxazolyl, 3-, 4-, 5-, 6- or 7-benzisoxazolyl, 2-, 4-, 5-, 6- or 7-benzothiazolyl, 2-, 4-, 5-, 6- or 7-benzisothiazolyl, 4-, 5-, 6- or 7-benz-2,1,3-oxadiazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl, 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl, 3-, 4-, 5-, 6-, 7- or 8-cinnolinyl, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl, 5- or 6-quinoxaliny, 2-, 3-, 5-, 6-, 7- or 8-2H-benzo-1,4-oxazinyl, furthermore preferably 1,3-benzodioxol-5-yl, 1,4-benzodioxan-6-yl, 2,1,3-benzothiadiazol-4- or -5-yl, or 2,1,3-benzoxadiazol-5-yl, which in each case is unsubstituted or mono-, di- or trisubstituted by substituents selected from carbonyl oxygen, F, Cl, Br, methyl, ethyl, propyl, phenyl, benzyl, -CH<sub>2</sub>-cyclohexyl, hydroxyl, methoxy, ethoxy, amino, methylamino, dimethylamino, nitro, cyano, carboxyl, methoxycarbonyl, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, acetamino, ureido, methylsulfonamino,

formyl, acetyl, aminosulfonyl, and methylsulfonyl, or

Het is 2,3-dihydro-2-, -3-, -4- or -5-furyl, 2,5-dihydro-2-, -3-, -4- or 5-furyl, tetrahydro-2- or -3-furyl, 1,3-dioxolan-4-yl, tetrahydro-2- or -3-thienyl, 2,3-dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 2,5-dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 1-, 2- or 3-pyrrolidinyl, tetrahydro-1-, -2- or -4-imidazolyl, 2,3-dihydro-1-, -2-, -3-, -4- or -5-pyrazolyl, tetrahydro-1-, -3- or -4-pyrazolyl, 1,4-dihydro-1-, -2-, -3- or -4-pyridyl, 1,2,3,4-tetrahydro-1-, -2-, -3-, -4-, -5- or -6-pyridyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, tetrahydro-2-, -3- or -4-pyranyl, 1,4-dioxanyl, 1,3-dioxan-2-, -4- or -5-yl, hexahydro-1-, -3- or -4-pyridazinyl, hexahydro-1-, -2-, -4- or -5-pyrimidinyl, 1-, 2- or 3-piperazinyl, 1,2,3,4-tetrahydro-1-, -2-, -3-, -4-, -5-, -6-, -7- or -8-quinolyl, 1,2,3,4-tetrahydro-1-, -2-, -3-, -4-, -5-, -6-, -7- or -8-isoquinolyl, 2-, 3-, 5-, 6-, 7- or 8- 3,4-dihydro-2H-benzo-1,4-oxazinyl, furthermore preferably 2,3-methylenedioxyphenyl, 3,4-methylenedioxyphenyl, 2,3-ethylenedioxyphenyl, 3,4-ethylenedioxyphenyl, 3,4-(difluoromethylenedioxy)phenyl, 2,3-dihydrobenzofuran-5- or 6-yl, 2,3-(2-oxomethylenedioxy)phenyl, 3,4-dihydro-2H-1,5-benzodioxepin-6- or -7-yl, 2,3-dihydrobenzofuranyl, 2,3-dihydro-2-oxofuranyl, 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxo-1*H*-pyridin-1-yl, 3-oxomorpholin-4-yl, 4-oxo-1*H*-pyridin-1-yl, 2,6-dioxopiperidin-1-yl, 2-oxopiperazin-1-yl, 2,6-dioxopiperazin-1-yl, 2,5-dioxopyrrolidin-1-yl, 2-oxo-1,3-oxazolidin-3-yl, 3-oxo-2*H*-pyridazin-2-yl, 2-caprolactam-1-yl, 2-hydroxy-6-oxopiperazin-1-yl, 2-methoxy-6-oxopiperazin-1-yl, or 2-azabicyclo[2.2.2]octan-3-on-2-yl.

36. (New): A compound according to claim 1, wherein  $\textcircled{\text{Y}}$  is phenyl, pyridyl or pyrimidinyl.

37. (New): A compound according to claim 35, wherein

A is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, 1-, 2- or 3-methylbutyl, 1,1-, 1,2- or 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-, 2-, 3- or 4-methylpentyl, 1,1-, 1,2-, 1,3-, 2,2-, 2,3- or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, 1,1,2- or 1,2,2-trimethylpropyl, linear or branched heptyl, octyl, nonyl, decyl, trifluoromethyl, pentafluoroethyl, 1,1,1-trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl; and

Ar is phenyl, naphthyl or biphenyl, which in each case is mono-, di- or trisubstituted

by substituents selected from A, fluorine, chlorine, bromine, iodine, hydroxyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, nitro, cyano, formyl, acetyl, propionyl, tri-fluoromethyl, amino, methylamino, ethylamino, dimethylamino, diethylamino, benzyloxy, sulfonamido, methylsulfonamido, ethylsulfonamido, propylsulfonamido, butylsulfonamido, dimethylsulfonamido, phenylsulfonamido, carboxyl, methoxycarbonyl, ethoxycarbonyl, and aminocarbonyl.

38. (New): A compound according to Claim 1, in which

R<sup>1</sup> is Hal, NO<sub>2</sub>, CF<sub>3</sub>, COOH, COOR or H,

R<sup>2</sup> is H,

R<sup>3</sup> is H, Hal, CO-NHR,

Y is phenyl, furyl, thienyl, pyrrolyl, imidazolyl, pyridyl or pyrimidinyl, and

X is O, S, SO<sub>2</sub>NH or NH.